«Never
before has PTK6 inhibition been shown to inhibit growth and induce cell death of ER + breast cancer cells, including those resistant to standard treatments for this subtype such as
tamoxifen,» said Hanna Irie, MD, PhD, Assistant Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences at The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and senior author of the study.